Precision Treatment for a Specific KRAS Mutation
KRAS is one of the most frequently altered cancer-driving genes, but for many years it was considered extremely difficult to target directly.
The identification of the KRAS G12C mutation created a new treatment opportunity.
Garsorasib is an oral KRAS G12C inhibitor designed to bind selectively to the mutated KRAS protein and block signaling that drives cancer-cell growth.
This treatment is relevant specifically to patients whose tumors carry the KRAS G12C mutation. It should not be assumed to work for other KRAS variants such as G12D, G12V or G13D.
A phase II study conducted across 43 hospitals in China evaluated garsorasib in patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer who had previously been treated with platinum-based chemotherapy and immune checkpoint inhibitors.
Patients received oral garsorasib twice daily.
The independently confirmed objective response rate was approximately 50%, meaning that about half of treated patients experienced a measurable reduction in tumor size.
This is clinically meaningful because patients in this setting have already received two of the major treatment classes commonly used for advanced NSCLC: chemotherapy and immunotherapy.
The treatment strategy is based on precision oncology rather than tumor location alone.
Before treatment, patients need molecular testing confirming KRAS G12C. Next-generation sequencing using tumor tissue or circulating tumor DNA can often identify the mutation.
Patients who may be evaluated include those with:
- Advanced or metastatic NSCLC
- Confirmed KRAS G12C mutation
- Previous exposure to standard systemic therapy
- Adequate liver, kidney and bone-marrow function
Treatment-related adverse events are common, and some patients experience severe adverse effects requiring dose interruption, reduction or supportive treatment.
Regular monitoring typically includes liver-function tests, complete blood counts, symptom assessment and periodic CT imaging.
Garsorasib represents a broader shift in lung-cancer treatment from a single diagnosis such as “non-small cell lung cancer” toward highly specific molecular categories. For a patient with KRAS G12C-positive disease, identifying the mutation can open a targeted treatment option that would not be relevant to patients with other KRAS alterations.
